MedPath

Third MMR vaccine dose in young adults

Completed
Conditions
MMR vaccinationMumps, Measles and RubellaMumps outbreakImmunogenicity and toleranceAntibody response and cellular immunityBMR vaccinatieBof, Mazelen en Rode HondBof uitbraakImmunogeniciteit en veiligheidAntistof respons en cellulaire immuniteit
Registration Number
NL-OMON20600
Lead Sponsor
ational Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control (CIb)
Brief Summary

https://pubmed.ncbi.nlm.nih.gov/33269296/ https://pubmed.ncbi.nlm.nih.gov/34211021/ https://pubmed.ncbi.nlm.nih.gov/31112277/

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
150
Inclusion Criteria

1. Healthy young adult 18-25 years of age

2. Previously been immunized with two doses of the MMR vaccine according to the Dutch
NIP (MMR-1 at ~14 months and MMR-2 at ~9 years)

Exclusion Criteria

1. Medical conditions that will severely affect immunological responses to vaccinations,
such as, but not limited to, cancer or an immune disorder.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary study parameters are the mumps-specific VN antibody concentrations<br>(against the vaccine- and currently circulating mumps virus strains) and IgG antibody<br>concentrations (including antibody avidity) measured in serum samples taken prior to,<br>and 10 days, 4 weeks, 1 year and 3 years following a third vaccine dose of MMR in healthy<br>young adults (18-25 years).
Secondary Outcome Measures
NameTimeMethod
-Frequency and intensity of the local and systemic adverse events<br /><br>- Mumps-specific IgA and IgG (saliva) prior to, and 4 weeks and 1 year following a third vaccine dose of MMR<br /><br>- The presence and frequency of mumps-specific memory and effector T- and B-cells in peripheral blood following MMR-3, in a voluntary subset of the participants prior to, 4 weeks and 1 year following a third vaccine dose of MMR<br /><br>-Serum IgG response against measles and rubella (components of the MMR vaccine)<br>prior to, 10 days, 4 weeks, 1 year and 3 years following a third vaccine dose of MMR
© Copyright 2025. All Rights Reserved by MedPath